Technology | May 19, 2015

FDA Clears Sutureless Epicardial Pacing Leads

Leads can be used in patients contraindicated for traditional leads

Greatbatch Medical, Myopore Sutureless Myocardial Pacing Lead

May 19, 2015 — A new epicardial pacing lead has been cleared by the U.S. Food and Drug Administration (FDA) as an option for the implant of a pacemaker, defibrillator, or cardiac resynchronization therapy (CRT) device. The lead is indicated when other types of leads cannot be implanted. Examples include patients who have small veins, congenital heart disease, abnormalities of the tricuspid valve or when other leads are already in place, preventing additional leads in the veins.

The Myopore Sutureless Myocardial Pacing Lead from Greatbatch Medical is a surgically implanted, insulated and sutureless wire with a screw-in tip that is part of a permanently implanted pacemaker, defibrillator or CRT device. The lead is implanted by opening the chest or a making a small incision under the breastbone. It is then placed on the surface of the heart muscle so the screw-in tip end can electrically stimulate (pace) the ventricles.

When placed on the surface of the heart as part of a pacemaker, the Myopore Lead paces the heart to assure that it beats at an appropriate rate. A CRT device uses two leads, one to pace each ventricle, either of which may be a Myopore Lead. A CRT device with two leads is intended to coordinate and improve the ventricles' timing to reduce symptoms of heart failure.

The Myopore Lead should not be used when a patient's heart is too thin or damaged and should not be implanted on the surface of the atria.

For more information: www.greatbatchmedical.com

Related Content

Abbott Announces MR-Conditional Labeling for Quadra Assura CRT-D and Fortify Assura ICD
Technology | Cardiac Resynchronization Therapy Devices (CRT) | January 03, 2018
Abbott announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for...
Biotronik Announces U.S. Launch of Edora HF-T QP CRT Pacemaker
Technology | Cardiac Resynchronization Therapy Devices (CRT) | August 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and commercial availability of Edora HF-T QP, an...
Biotronik Launches DX Technology for U.S. Heart Failure Patients
News | Cardiac Resynchronization Therapy Devices (CRT) | July 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and availability of the Intica DX and Intica...
Videos | Cardiac Resynchronization Therapy Devices (CRT) | May 23, 2017
This video, provided by ERB, demonstrates the function and implantation of the WiSE CRT (Wireless Stimulation Endocar
Biotronik Announces FDA Approval of MultiPole Pacing
Technology | Cardiac Resynchronization Therapy Devices (CRT) | May 11, 2017
May 11, 2017 — Biotronik announced U.S.
Biotronik Launches First FDA-Approved CRM Devices with MRI AutoDetect Technology
Technology | Cardiac Resynchronization Therapy Devices (CRT) | May 10, 2017
Biotronik announced the availability of the first U.S. Food and Drug Administration (FDA)-approved cardiac rhythm...
NICE Recommends Boston Scientific CRT-Ds With EnduraLife Battery Technology for Heart Failure Treatment
News | Cardiac Resynchronization Therapy Devices (CRT) | April 14, 2017
The National Institute for Health and Care Excellence (NICE) recently issued medical technology guidance recommending...
Biotronik, Edora series, pacemakers, CRT-Ps
Technology | Cardiac Resynchronization Therapy Devices (CRT) | March 23, 2017
March 23, 2017 — Biotronik announced the European launch of the Edora series, its smallest series of...
Overlay Init